KnipBio completes trial on feed efficacy product
US firm KnipBio has successfully completed a feed efficacy trial on Atlantic salmon, marking the third version of its single-cell protein to pass quality and efficacy trials. Read more >>
14Sep
Related Posts
17Apr
eSight Headsets Provide Vision to Impaired
A Toronto-based company called eSight is bringing an end to legal blindness with their groundbreaking technology. Read more >> read more
05Feb
RevBio Enters the Animal Health Market to Help Improve Canine Dental Care
As its first veterinary application, RevBio, Inc. announced that it has initiated a clinical study to validate the use of... read more
30Dec
Spark Investment Management LLC Has $3,933,000 Position in Carbonite Inc.
Spark Investment Management LLC raised its stake in Carbonite Inc. (NASDAQ:CARB) by 51.8% during the third quarter, according to its... read more
20May
PNC Bank Expands Financial Wellness Offerings With PNC Student Debt Solution, Powered by Candidly™
PNC Bank, N.A. today announced an expansion of its financial wellness offerings for clients through the introduction of PNC Student... read more
15Mar
Regroup Mass Notification at the 5th Annual Ellucian Live Conference
Regroup Mass Notification, industry-leading provider of emergency and day-to-day communication solutions, announced that it will be attending the Ellucian Live... read more
14Mar
Myomo Welcomes 13 New Center of Excellence Locations
Myomo, Inc., a commercial stage medical robotics company, today announced the addition of three new orthotics and prosthetics (O&P) practices... read more
01Jul
Corbus Pharmaceuticals Expands Pipeline with Two New mAbs
Corbus Pharmaceuticals has licensed two integrin-targeting mAbs, expanding its therapeutics pipeline into inflammatory, fibrotic, and metabolic diseases as well as... read more
10Dec
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that... read more
29Jul
Siamab Therapeutics Announces Publication in PLOS ONE of Positive Data from Preclinical Studies of its ST1 Antibody Therapeutic in Development for Ovarian Cancer
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, today announced the publication of positive preclinical data for... read more
06May
Hoth Therapeutics Expands Partnership with Zylö Therapeutics, Inc.
Hoth Therapeutics, Inc., a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc. Mr. Robb... read more